What is the ROE (Return on Equity) of Formycon this year?
The ROE of Formycon this year is 0.15 undefined.
Formycon ROE 2025
Formycon ROE
0.15
Ticker
FYB.DE
ISIN
DE000A1EWVY8
WKN
A1EWVY
In 2025, Formycon's return on equity (ROE) was 0.15, a 49.36% increase from the 0.1 ROE in the previous year.
Formycon Aktienanalyse
What does Formycon do?
Formycon AG is a German biotechnology company that was founded in 2010 in Martinsried near Munich. The company's history mainly began with the development of an innovative technology concept that allows for the cost-effective and efficient production of biosimilars. The market entry started in 2017 with the launch of the first proprietary biosimilar on the European market. The core business of Formycon AG is the production and distribution of biosimilars. These are biological drugs that have a similar structure and efficacy to already approved original drugs. The development of biosimilars is complex due to the elaborate manufacturing process and high-quality assurance requirements, requiring innovative ideas and technologies. Formycon AG has developed its innovative platform technology, FORMYCON® NEXT LEVEL, which allows the company to cost-effectively produce large quantities of proteins used in cancer therapy, immunotherapy, and the treatment of autoimmune diseases. Formycon AG is divided into various divisions, including research and development, production, and distribution. In research and development, new biosimilars and other innovative technologies are developed to further improve production processes. Production takes place in a dedicated biotechnological production facility in Roth near Nuremberg, where up to eight different medications can be produced simultaneously. In the distribution sector, Formycon AG collaborates with partners who market and distribute the biosimilars in different countries. The company operates internationally, with a presence in Europe, the USA, and Asia. The biosimilars produced by Formycon AG are a cost-effective alternative to the existing original drugs. The products are used in the fields of oncology, immunology, and ophthalmology, offering patients a chance to receive effective therapy at an affordable price. Successful marketing and high demand contribute to positive company development. In 2020, Formycon AG generated a revenue of 25 million euros and currently employs approximately 150 staff members. An example of a biosimilar produced by Formycon AG is the drug FYB202, which is used for the treatment of breast, ovarian, and salivary gland cancer. It is a replica of the breast cancer medication Herceptin®, developed and distributed by the Swiss company Roche. The FYB202 biosimilar has shown in clinical studies that it is similarly effective as Herceptin® but represents a more cost-effective alternative for patients. Overall, Formycon AG pursues a sustainable business model with a focus on the development of cost-effective biosimilars. The innovative technology and focus on cost-effective production enable the company to achieve a strong market presence and offer an effective alternative to conventional drugs. Formycon ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Formycon's Return on Equity (ROE)
Formycon's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Formycon's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Formycon's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Formycon’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Formycon stock
How has the Return on Equity (ROE) of Formycon developed compared to the previous year?
The ROE of Formycon has increased by 49.36% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Formycon?
A high ROE indicates that Formycon generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Formycon?
A low ROE can indicate that Formycon is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Formycon affect the company?
A change in ROE (Return on Equity) of Formycon can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Formycon?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Formycon?
Some factors that can influence Formycon's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Formycon pay?
Over the past 12 months, Formycon paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Formycon is expected to pay a dividend of 0 EUR.
What is the dividend yield of Formycon?
The current dividend yield of Formycon is .
When does Formycon pay dividends?
Formycon pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Formycon?
Formycon paid dividends every year for the past 0 years.
What is the dividend of Formycon?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Formycon located?
Formycon is assigned to the 'Health' sector.
Wann musste ich die Aktien von Formycon kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Formycon from 1/4/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/4/2025.
When did Formycon pay the last dividend?
The last dividend was paid out on 1/4/2025.
What was the dividend of Formycon in the year 2024?
In the year 2024, Formycon distributed 0 EUR as dividends.
In which currency does Formycon pay out the dividend?
The dividends of Formycon are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Formycon stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Formycon
Our stock analysis for Formycon Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Formycon Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
